Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Normothermic Regional Perfusion Experience of Organ Procurement Organizations in the US
Sellers, Marty T. , Philip, Jennifer L. , Cauwels, Roxane L., Croome, Kristopher P. , Hoffman, Jordan R. , Neidlinger, Nikole , Reynolds, Andrea, Edwards, John M. , Croome, Kris P , Brubaker, Aleah L. , Hoffman, Jordan R., Wall, Anji

JAMA Network Open | October 24, 2024 | Volume: 7 | Issue: 10 | Pages: e2440130

10.1001/jamanetworkopen.2024.40130 | PMID 39446328 Get It

Importance Despite the unmet need for donor organs, organ use from donation after circulatory determination of death (DCD) donors has been limited by inferior transplant outcomes. Normothermic regional perfusion (NRP) improves recipient outcomes and organ utilization from DCD donors. There is variability in NRP policies and experience among US organ procurement organizations (OPOs). Objectives To determine OPO experience, identify operational inconsistencies, and explore needs related to NRP. Design, Setting, and Participants This survey study included 55 OPOs in the US that had recovered DCD organs and completed a survey on operational, administrative, and educational components related to NRP in November to December 2023. Data analysis was performed from February to April 2024. Main Outcome and Measures The primary outcome was the number of OPOs participating in and/or anticipating NRP participation. Secondary outcomes were NRP implementation barriers, OPO education practices, and future needs regarding consensus NRP recommendations and standards. Results Of 55 respondents, 11 (20%) were chief executive officers, 8 (15%) were chief operating officers, and 36 (65%) were medical directors or chief clinical officers. Forty-nine OPOs facilitated NRP cases: 26 OPOs (53%) facilitated both thoracoabdominal NRP (TA-NRP) and abdominal NRP (A-NRP) cases, 16 OPOs (33%) facilitated only TA-NRP, and 7 OPOs (14%) facilitated only A-NRP. OPOs reported 606 NRP cases (421 TA-NRP [69%], 185 A-NRP [31%]); median (range) case experience was 8 (1-52). Fifty-two of 55 OPOs (95%) thought standardized guidance documents would be helpful. All 49 OPOs facilitated NRP at a transplant center’s request; 39 (80%) had NRP initiated by a nonlocal transplant center. Twenty-three of 49 OPOs (47%) participated in NRP without a policy and without a policy pending approval. Positive donor hospital feedback was received by 29 OPOs (59%), primarily focused on increased organs transplanted and prerecovery communication. Allocation challenges were experienced by 21 OPOs (43%); their median (range) case volume was higher than those with no reported allocation challenges (11 [3-52] vs 6.5 [1-29]; P = .03). Eleven OPOs (22%) had incorporated NRP into general donor hospital education. Conclusions In this survey study of US OPOs, wide variation existed with respect to NRP experience and practice. Allocation challenges occurred more frequently with increased NRP experience. NRP guidelines and standardization were desired by most OPOs to decrease allocation challenges and maximize the gift of organ donation.
Epstein-Barr virus-driven T-cell lymphoma with haemophagocytic lymphohistiocytosis: a life-threatening disorder extending beyond childhood
Kozai, Landon, Takahashi, Toshiaki , Macapagal, Sharina , Wannaphut, Chalothorn , Nishimura, Yoshito

European Journal of Case Reports in Internal Medicine | October 24, 2024 | Volume: 11 | Issue: 11 | Pages: No page available

10.12890/2024_004931 | PMID 39525447 Get It

An 18-year-old previously healthy Filipino male presented with abdominal pain, vomiting, dyspnoea and fever. Initial investigations revealed severe hepatosplenomegaly, pancytopaenia, elevated liver enzymes, coagulopathy and extremely high ferritin levels. Bone marrow biopsy confirmed an abnormal CD8+ T-cell population with haemophagocytosis. Extensive workup was performed, and he was ultimately diagnosed with haemophagocytic lymphohistiocytosis (HLH) secondary to Epstein-Barr virus-positive T-cell lymphoma of childhood (EBV-TCL), a rare and aggressive malignancy. Despite the initiation of modified dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy along with high-dose glucocorticoids, the patient did not respond to the treatment and expired. This case underscores the critical importance of early recognition and prompt intervention in EBV-TCL-associated HLH which is a unique condition and a rare entity. The diagnosis of this entity can be particularly challenging, given its rapid progression and high mortality rate. Therefore, timely diagnosis and the initiation of appropriate therapy are essential for improving patient outcomes. General medicine providers play a key role in identifying warning signs to avoid delays in treatment initiation.
Reply to Ching-Pin et al
Alsakarneh, Saqr , Ghoz, Hassan, Alsakarneh, Saqr G , Hashash, Jana G. , Farraye, Francis A.

American Journal of Gastroenterology | October 24, 2024 | Volume: 120 | Issue: 3 | Pages: 682-682

10.14309/ajg.0000000000003102 | PMID 39445698 Get It

Efficacy and toxicity analysis of selective BET bromodomain inhibitors in models of inflammatory liver disease
Doskey, Luke C. , Scholtz, Cole R. , Vail, Nora R. , Khanal, Shalil , Lee, Amani, Kandanur, Sai Giridhar Sarma , Hoell, Zachariah J. , Huehls, Amelia M. , Issa, Mohamed, Kostallari, Enis , Cao, Sheng , Shah, Vijay H. , Kostallari, Enis , Lee, Amani L. , Issa, Mohamed R , Reid, Joel M. , Malhi, Harmeet , Pomerantz, William C. K.

No container title available | October 24, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.26434/chemrxiv-2024-lm1zq Get It

BET bromodomain inhibitors demonstrate significant promise as anti-inflammatory agents targeting a variety of inflammatory disorders. However, clinical data has demonstrated that the administration of non-selective BET bromodomain inhibitors has led to significant dose-limiting toxicity in clinical settings. More selective inhibitors of the second BET bromodomains, referred to as pan-D2 inhibitors, are better tolerated, however their efficacy varies significantly depending on disease indication. Here, we use three orally bioavailable inhibitors, 1–3, that are either selective for the first N-terminal bromodomain of BRD4 (BRD4-D1 selective), or pan-D1 biased, for assessing their cellular and in vivo efficacy and safety profile in two models of inflammatory liver disease. We compare their effects to known pan-D2 and pan-BET inhibitors. Our results show that pan-D1 biased inhibitor, 3, is as efficacious as the pan-BET inhibitor I-BET151 in reducing inflammation from LPS-induced and drug-induced toxicity, whereas pan-D2 inhibitors are less effective. BRD4-D1 selective inhibitors, 1 and 2, are also efficacious; however, new inhibitors with improved cellular target engagement will be necessary to more thoroughly assess their effects. Finally, BRD4-D1 selective inhibitors are better tolerated in a preclinical model of thrombocytopenia than pan-D1 biased inhibitors, while gastrointestinal (GI) toxicity may be a BRD4-driven effect. These results highlight the importance of assessing specific BET protein and bromodomain functions due to their varying roles in diverse disease models.
A Bundle of the “Top 10” Outpatient Parenteral Antimicrobial Therapy Publications in 2023
Childs‐Kean, Lindsey M. , Beieler, Alison M , Cortés-Penfield, Nicolás , Keller, Sara C. , Rivera, Christina G. , Yoke, Leah H , Mahoney, Monica V. , Yoke, Leah H , Mahoney, Monica V , Rivera, Christina G , Keller, Sara C , Ryan, Keenan

Open Forum Infectious Diseases | October 24, 2024 | Volume: 11 | Issue: 11 | Pages: No page available

10.1093/ofid/ofae635 | PMID 39507884 Get It

Abstract Outpatient parenteral antimicrobial therapy (OPAT) has become more common in infectious diseases practice settings. Similarly, OPAT-related publications have also increased. The objective of this article was to summarize clinically important OPAT-related publications from 2023. Eighty-one articles were found on initial search, with 52 meeting inclusion criteria. A survey containing the 19 articles that had at least 1 citation was sent to an email listserv of multidisciplinary clinicians with OPAT experience. This article summarizes the “top 10” 2023 OPAT articles from the survey results.
Anomalous education: You can't bypass electrodiagnostic training in PM&R residency
Howard, Ileana M. , Tan, Faye, Irwin, Robert W., Laughlin, Ruple S. , Chiodo, Anthony , Grant, Peter A., Adkins, S., Krzesniak‐Swinarska, Monika, Malhotra, Gautam , Quan, Dianna , Franz, Colin K.

PM&R | October 24, 2024 | Volume: 17 | Issue: 3 | Pages: 347-348

10.1002/pmrj.13281 | PMID 39444112 Get It

SOS1‐Related Noonan Syndrome and Sudden Cardiac Arrest in the Absence of Cardiomyopathy—An Arrhythmia Phenotype?
Cirelli, Michael A. , Wackel, Philip L. , Gavrilova, Ralitza H. , Qureshi, M. Yasir , Boucher, Lauren M., Niaz, Talha , Qureshi, Muhammad Y , Javed, Rabia, Dearani, Joseph A. , Boucher, Lauren M.

American Journal of Medical Genetics Part A | October 24, 2024 | Volume: 197 | Issue: 3 | Pages: No page available

10.1002/ajmg.a.63912 | PMID 39444097 Get It

ABSTRACTNoonan syndrome (NS) is a predominantly autosomal dominant condition with various cardiac and extra‐cardiac manifestations. Although it has been linked with atrial arrhythmias, ventricular arrhythmias are extremely rare in the absence of underlying structural cardiac abnormalities. We report an instance of aborted sudden cardiac arrest in a 7‐year‐old male with a confirmed SOS1 variant and a lack of evidence to support a structural cardiac, metabolic, or infectious etiology. This is the second reported instance of sudden cardiac arrest related to ventricular fibrillation in a child with SOS1‐related NS in the absence of any structural cardiac defects. Although no definitive correlation can be ascertained from a limited existing body of knowledge surrounding SOS1 and ventricular fibrillation unrelated to structural heart defects, it provokes the idea of an arrhythmia phenotype and future research is warranted to guide proper clinical treatment, monitoring, and management of such individuals.
Have We Solved the Chicken-and-Egg Conundrum? Hippocampal Sclerosis and Temporal Lobe Epilepsy Following Febrile Status Epilepticus: Results of the 10-Year Follow-up FEBSTAT Study
Feyissa, Anteneh M. , Feyissa, A M

Epilepsy Currents | October 24, 2024 | Volume: 24 | Issue: 6 | Pages: 400-402

10.1177/15357597241279746 | PMID 39540133 Get It

[Box: see text]
CNS manifestations in acute and chronic graft-versus-host disease
Lambert, Nicolas , Forte, Florence, Monseur, Justine, Raus, Nicole, Shultz, Carl , Balaguer‐Roselló, Aitana , Gil‐Perotín, Sara , Brijs, Jan , Chauvet, Paul , Carré, Martin , Dulămea, Adriana Octaviana , Salmenniemi, Urpu , Nguyen, Stéphanie , Smallbone, Portia , González‐Vicent, Marta , Willems, Évelyne, Baron, Frédéric , Servais, Sophie , Béguin, Yves , Maquet, Pierre , Group, the CNS-GvHD Study, Lambert, Nicolas, Monseur, Justine, Raus, Nicole, Shultz, Carl, Brijs, Jan, Gavriilaki, Maria, Dulamea, Adriana Octaviana, Tănase, Alina , Salmenniemi, Urpu, Butera, Sara , Piekarska, Agnieszka , Davies, J. M., Labussière-Wallet, Hélène, D’Aveni, Maud , Willems, Evelyne, Gil-Perotín, Sara , Chalandon, Yves , Santoro, Jonathan D , Servais, Sophie , Lambert, Nicolas , Moussaoui, Majdouline El , Raus, Nicole, Polushin, Alexey Yu. , Michonneau, David , Hogan, William J. , Gavriilaki, Maria , Chalandon, Yves , Duminuco, Andrea , Ram, Ron , García‐Cadenas, Irene , Porto, Gaetana , Santoro, Jonathan D. , Group, the CNS-GvHD Study, Lambert, Nicolas, Monseur, Justine, Raus, Nicole, Skiba, Iaroslav B. , Shultz, Carl, Brijs, Jan, Gavriilaki, Maria, Sakellari, Ioanna , Dulamea, Adriana Octaviana, Chantepie, Sylvain , Salmenniemi, Urpu, Loschi, Michael L. , Martino, Massimo , Mensah‐Glanowska, Patrycja , Labussière-Wallet, Hélène, Hamadani, Mehdi , Willems, Evelyne

Brain | October 23, 2024 | Volume: 148 | Issue: 4 | Pages: 1122-1133

10.1093/brain/awae340 | PMID 39442000 Get It

Abstract Despite the growing evidence supporting the existence of CNS involvement in acute and chronic graft-versus-host disease (CNS-GvHD), the characteristics and course of the disease are still largely unknown. In this multicentre retrospective study, we analysed the clinical, biological, radiological and histopathological characteristics, as well as the clinical course of 66 patients diagnosed with possible CNS-GvHD (pCNS-GvHD), selected by predetermined diagnostic criteria. Results were then contrasted depending on whether pCNS-GvHD onset occurred before or after Day 100 following allogeneic haematopoietic stem cell transplantation (allo-HSCT). The median time between allo-HSCT and pCNS-GvHD onset was 149 days (interquartile range25–75 48–321), and pCNS-GvHD onset occurred before Day 100 following transplantation in 44% of patients. The most frequent findings at presentation were cognitive impairment (41%), paresis (21%), altered consciousness (20%), sensory impairment (18%) and headache (15%). Clinical presentation did not significantly differ between patients with pCNS-GvHD occurring before or after Day 100 following transplantation. Brain MRI found abnormalities compatible with the clinical picture in 57% of patients, while CT detected abnormalities in only 7%. Seven patients had documented spinal cord MRI abnormalities, all of them with pCNS-GvHD occurring after Day 100 following transplantation. In the CSF, the white blood cell count was increased in 56% of the population (median 18 cells/μl). Histopathological analyses were performed on 12 specimens and were suggestive of pCNS-GvHD in 10. All compatible specimens showed parenchymal and perivascular infiltration by CD3+ and CD163+ cells. Immunosuppressive therapy was prescribed in 97% of patients, achieving complete clinical response in 27%, partial improvement in 47% and stable disease in 6%. Response to immunosuppressive therapy did not differ significantly between patients with pCNS-GvHD occurring before or after Day 100 following transplantation. Clinical relapse was observed in 31% of patients who initially responded to treatment. One-year overall survival following pCNS-GvHD onset was 41%. Onset before Day 100 following haematopoietic stem cell transplantation [hazard ratio with 95% confidence interval: 2.1 (1.0–4.5); P = 0.041] and altered consciousness at initial presentation [3.0 (1.3–6.7); P = 0.0077] were associated with a reduced 1-year overall survival probability. Among surviving patients, 61% had neurological sequelae. This study supports that immune-mediated CNS manifestations may occur following allo-HSCT. These can be associated with both acute and chronic GvHD and carry a grim prognosis. The clinical presentation as well as the radiological and biological findings appear variable.